The Analyst celebrate partnership with Sarcoma UK at special event 10 Downing Street
Our Founder Mark Hiley accepted an award on behalf of The Analyst at from a national cancer charity at a ceremony in Downing Street.
It is in the UK’s interest to treat investment research as a public good
We featured in the Financial Times today talking about the challenges of independent research.
For bear stock pickers, 2023 is full of rich pickings
The Analyst is featured Reuter article focusing on how Short researchers use forensic accounting, lessons learned and their expectations for 2023.
Sarcoma UK thanks £1 million partner with reception at the Lord Mayor’s Mansion House
We celebrated our partnership with Sarcoma UK last week at a reception and silent auction held at Mansion House.
Bernd Ondruch and Mark Hiley: Tales from the Frontlines of Short Selling
Mark Hiley speaks to Bernd Ondruch, founder & CIO of Astellon Capital Partners, on Real Vision.
The Analyst Has Spotted Wirecard Red Flags since 2014
Mark Hiley discusses the red flags uncovered through years of research on Wirecard.
Wirecard and Why The Analyst Was Sceptical
The New York Times speaks to The Analyst about irregularities noticed at Wirecard during our years of coverage.
The Challenges of Rooting Out Corporate Frauds
Founder Mark Hiley speaks to Bloomberg about the difficulties faced during six years of coverage on Wirecard.
How The Analyst Spotted NMC Health
The Times profiles how The Analyst spotted red flags in NMC Health months ahead of market.
The Analyst Founder on AIM in The Sunday Times
The Analyst founder Mark Hiley comments for The Sunday Times on the risks in AIM stocks.
